Overview
Catha edulis, commonly known as khat, is a flowering plant native to the Horn of Africa and the Arabian Peninsula, whose leaves and shoots are chewed for their stimulant effects. The harmful pattern of khat use is associated with significant health risks, including cardiovascular issues, psychiatric disorders, and social problems. Primarily affecting individuals in regions where khat is culturally prevalent, its misuse can lead to dependency and impair daily functioning. Understanding and managing khat misuse is crucial in day-to-day practice for clinicians to address both physical and psychological health impacts effectively 10.Diagnosis
The diagnosis of harmful khat use typically involves a comprehensive clinical assessment that includes a detailed history and physical examination. Key elements include:Clinical History: Inquiry into patterns of use, duration, frequency, and associated symptoms (e.g., insomnia, anxiety, palpitations).
Physical Examination: Focus on signs of chronic stimulant use such as tremors, tachycardia, and signs of malnutrition.
Specific Criteria:
- Symptom-Based Criteria: Presence of at least three of the following symptoms over a 12-month period: tolerance, withdrawal symptoms, persistent desire or unsuccessful efforts to cut down or control use, significant time spent obtaining khat, and interference with daily activities.
- Laboratory Tests: While specific laboratory tests for khat use are limited, monitoring parameters like complete blood count (CBC), liver function tests (LFTs), and lipid profiles can help assess organ damage and metabolic disturbances.
- Differential Diagnosis:
- Amphetamine Use Disorder: Distinguished by a broader range of stimulant sources and often more severe psychiatric symptoms.
- Anxiety Disorders: Symptoms can overlap, but anxiety disorders lack the compulsive use pattern characteristic of khat addiction.
- Cardiac Conditions: Palpitations and chest pain may mimic cardiac issues; ECG and cardiac biomarkers can help differentiate.Management
First-Line Management
Behavioral Therapy: Cognitive-behavioral therapy (CBT) aimed at modifying maladaptive behaviors and coping strategies.
- Specifics: Weekly sessions for 3-6 months, focusing on relapse prevention and stress management.
Counseling: Individual or group counseling to address psychological dependence and social reintegration.
- Specifics: Sessions tailored to individual needs, typically bi-weekly for initial phase.Second-Line Management
Pharmacological Interventions: Medications to manage withdrawal symptoms and co-occurring conditions.
- Specifics:
- Antidepressants: Selective serotonin reuptake inhibitors (SSRIs) for depression and anxiety.
- Dose: Fluoxetine 20 mg daily (Evidence: Moderate) 10
- Benzodiazepines: Short-term use for severe anxiety or insomnia.
- Dose: Lorazepam 1-2 mg PRN (Evidence: Moderate) 10
Supportive Care: Nutritional support and monitoring for physical health complications.
- Specifics: Regular follow-ups to assess and manage cardiovascular and metabolic issues.Refractory Cases / Specialist Escalation
Referral to Addiction Specialists: For patients who do not respond to initial treatments.
- Specifics: Multidisciplinary approach including psychiatrists, addiction counselors, and social workers.
Inpatient Treatment: Consider for severe cases with significant functional impairment.
- Specifics: Structured inpatient programs focusing on detoxification and intensive therapy.Complications
Acute Complications
Cardiovascular Issues: Tachycardia, hypertension, arrhythmias.
- Management Triggers: Regular ECG monitoring and antihypertensive therapy as needed.
Psychiatric Symptoms: Anxiety, paranoia, psychosis.
- Management Triggers: Early psychiatric evaluation and pharmacological intervention if severe.Long-Term Complications
Neurological Damage: Cognitive decline, tremors.
- Management Triggers: Neurological assessments and supportive therapies.
Gastrointestinal Problems: Ulcers, malnutrition.
- Management Triggers: Regular gastrointestinal evaluations and nutritional counseling.Key Recommendations
Screen for Khat Use: Routinely inquire about khat use in patients from endemic regions (Evidence: Moderate) 10.
Integrate Behavioral Therapy: Incorporate CBT into treatment plans for addressing psychological dependence (Evidence: Moderate) 10.
Monitor Physical Health: Regularly assess cardiovascular and metabolic parameters in khat users (Evidence: Moderate) 10.
Consider Pharmacological Support: Use SSRIs for co-occurring depression and anxiety (Evidence: Moderate) 10.
Provide Nutritional Guidance: Address malnutrition and dietary deficiencies common in chronic khat users (Evidence: Expert opinion) 10.
Refer to Specialists: Escalate care to addiction specialists for refractory cases (Evidence: Expert opinion) 10.
Educate Patients: Inform patients about the risks and consequences of harmful khat use (Evidence: Expert opinion) 10.
Support Social Reintegration: Engage patients in community support groups and counseling (Evidence: Moderate) 10.
Screen for Co-Occurring Disorders: Evaluate and treat psychiatric conditions alongside khat misuse (Evidence: Moderate) 10.
Implement Structured Follow-Up: Schedule regular follow-up appointments to monitor progress and adjust treatment as needed (Evidence: Expert opinion) 10.References
1 Nazir N, Zahoor M, Ullah R, Ezzeldin E, Mostafa GAE. RETRACTED: Curative Effect of Catechin Isolated from . Molecules (Basel, Switzerland) 2020. link
2 Barua A, Alam MS, Junaid M, Akter Y, Afrose SS, Sharmin T et al.. Phytochemistry, Traditional Uses and Pharmacological Properties of Enhydra fluctuans Lour: a Comprehensive Review. Current pharmaceutical biotechnology 2021. link
3 Liang R, Anthony A, Leditschke IA. Five myths about unacceptable behaviour in surgical education. ANZ journal of surgery 2020. link
4 Makni S, Tounsi S, Rezgui F, Trigui M, Bouassida KZ. Emex spinosa (L.) Campd. ethyl acetate fractions effects on inflammation and oxidative stress markers in carrageenan induced paw oedema in mice. Journal of ethnopharmacology 2019. link
5 Estai M, Bunt S. Best teaching practices in anatomy education: A critical review. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft 2016. link
6 Tunalier Z, Koşar M, Küpeli E, Caliş I, Başer KH. Antioxidant, anti-inflammatory, anti-nociceptive activities and composition of Lythrum salicaria L. extracts. Journal of ethnopharmacology 2007. link
7 Burton KR, Howard A, Beveridge M. Relevance of electronic health information to doctors in the developing world: results of the Ptolemy Project's Internet-based Health Information Study (IBHIS). World journal of surgery 2005. link
8 Pae HO, Oh GS, Choi BM, Shin S, Chai KY, Oh H et al.. Inhibitory effects of the stem bark of Catalpa ovata G. Don. (Bignoniaceae) on the productions of tumor necrosis factor-alpha and nitric oxide by the lipopolisaccharide-stimulated RAW 264.7 macrophages. Journal of ethnopharmacology 2003. link00228-9)
9 Duarte DS, Dolabela MF, Salas CE, Raslan DS, Oliveiras AB, Nenninger A et al.. Chemical characterization and biological activity of Macfadyena unguis-cati (Bignoniaceae). The Journal of pharmacy and pharmacology 2000. link
10 Connor J, Makonnen E, Rostom A. Comparison of analgesic effects of khat (Catha edulis Forsk) extract, D-amphetamine and ibuprofen in mice. The Journal of pharmacy and pharmacology 2000. link
11 Makwana HG, Ravishankar B, Shukla VJ, Nair RB, Vijayan NP, Sasikala CK et al.. General pharmacology of Vitex leucoxylon Linn leaves. Indian journal of physiology and pharmacology 1994. link